D
Doreen Massie
Researcher at Aberdeen Royal Infirmary
Publications - 5
Citations - 258
Doreen Massie is an academic researcher from Aberdeen Royal Infirmary. The author has contributed to research in topics: Epidermal growth factor receptor & Gefitinib. The author has an hindex of 5, co-authored 5 publications receiving 222 citations.
Papers
More filters
Journal ArticleDOI
Deregulation of EIF4E: a novel mechanism for autism
M. Neves-Pereira,Berndt Müller,Doreen Massie,Justin H. G. Williams,P. C. M. O'brien,A. Hughes,Sanbing Shen,David St Clair,Zosia Miedzybrodzka +8 more
TL;DR: The findings raise the exciting possibility that pharmacological manipulation of EIF4E may provide therapeutic benefit for those with autism caused by disturbance of the converging pathways controlling Eif4E activity.
Journal ArticleDOI
Gefitinib and EGFR Gene Copy Number Aberrations in Esophageal Cancer.
Russell D. Petty,Asa Dahle-Smith,David A J Stevenson,Aileen Osborne,Doreen Massie,Caroline Clark,Graeme I. Murray,Susan J Dutton,Corran Roberts,Irene Chong,Wasat Mansoor,Joyce Thompson,Mark Harrison,Anirban Chatterjee,Stephen Falk,Sean Elyan,Angel Garcia-Alonso,David Walter Fyfe,Jonathan Wadsley,Ian Chau,David Ferry,Zosia Miedzybrodzka +21 more
TL;DR: EGFR CNG assessed by FISH appears to identify a subgroup of patients with esophageal cancer who may benefit from gefitinib as a second-line treatment, and anti-EGFR therapies should be investigated in prospective clinical trials in different settings in EGFR FISH-positive and, in particular, EGFR-amplified esophagal cancer.
Journal ArticleDOI
Epidermal growth factor receptor copy number gain (EGFR CNG) and response to gefitinib in esophageal cancer (EC): Results of a biomarker analysis of a phase Ill trial of gefitinib versus placebo (TRANS-COG).
Russell D. Petty,Asa Dahle-Smith,Zosia Miedzybrodzka,Susan J Dutton,Graeme I. Murray,David A J Stevenson,Doreen Massie,Aileen Osbourne,Caroline Clark,Wasat Mansoor,Joyce Thompson,Mark Harrison,Anirban Chatterjee,Stephen Falk,Seanmp Elyan,Angel Garcia-Alonso,D. Fyfe,Ian Chau,Diane Collinson,David Ferry +19 more
TL;DR: Improved disease control rates, improved patient reported outcomes, and progression free survival were seen with G-indicative of rapid and durable responses that were observed in a subset.
Journal ArticleDOI
Epidermal Growth Factor (EGFR) copy number aberrations in esophageal and gastro-esophageal junctional carcinoma.
Asa Dahle-Smith,David A J Stevenson,Doreen Massie,Graeme I. Murray,Susan J. Dutton,Corran Roberts,David Ferry,Aileen Osborne,Caroline Clark,Russell D. Petty,Zosia Miedzybrodzka,Zosia Miedzybrodzka +11 more
TL;DR: A scoring system in EC based upon established systems for EGFR fluorescence in-situ hybridisation (FISH) in lung cancer and applied in a series of 160 patients with advanced EC identifies a significant subgroup (20.0 %) of FISH positive patients.
Patent
Treatment and diagnosis of behavioural disorders
TL;DR: In this article, the identification of a novel drug target for use in the treatment of behavioural disorder, in particular, the invention provides compounds capable of modulating the expression, function and/or activity of eIF4E, for using in treating a behavioural disorder as well as methods of identifying the same.